Regulatory documents show that US pharmaceutical company AbbVie (ABBV.US) lowered its adjusted earnings per share forecast for the full year to $10.61-$10.81, down from the previous forecast of $11.13-$11.33, while analysts expect it to be $11.25.
AbbVie also lowered its adjusted earnings per share forecast for the second quarter from $3.05-$3.09 to $2.53-$2.57 due to expenses related to $937 million in asset acquisitions, cooperation, licensing agreements, and other related expenses incurred during the quarter.
AbbVie is scheduled to announce its second-quarter earnings on July 25th.